# Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

> **NCT00353678** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 1141 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** YM150

## Key facts

- **NCT ID:** NCT00353678
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 1141 (ACTUAL)
- **Last updated:** 2013-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353678, "Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00353678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*